Avantor® Reports Second Quarter 2025 Results
Avantor (NYSE:AVTR) reported mixed Q2 2025 financial results with net sales of $1.68 billion, showing a 1% decrease year-over-year, while organic revenue remained flat. The company posted net income of $64.7 million, down from $92.9 million in Q2 2024, with diluted EPS of $0.09 and adjusted EPS of $0.24.
The Laboratory Solutions segment saw a 3% decline in net sales to $1.12 billion, while Bioscience Production grew 3% to $561.3 million. The company generated operating cash flow of $154.4 million and free cash flow of $125.4 million, maintaining an adjusted net leverage of 3.2x.
Additionally, Avantor announced a significant leadership change, with Emmanuel Ligner appointed as the new President and CEO, effective August 18, 2025, replacing Michael Stubblefield.
Avantor (NYSE:AVTR) ha riportato risultati finanziari misti per il secondo trimestre del 2025, con vendite nette pari a 1,68 miliardi di dollari, registrando un calo dell'1% rispetto all'anno precedente, mentre i ricavi organici sono rimasti stabili. L'azienda ha registrato un utile netto di 64,7 milioni di dollari, in calo rispetto ai 92,9 milioni del secondo trimestre 2024, con un utile per azione diluito di 0,09 dollari e un utile per azione rettificato di 0,24 dollari.
Il segmento Laboratory Solutions ha subito una diminuzione del 3% nelle vendite nette, attestandosi a 1,12 miliardi di dollari, mentre Bioscience Production è cresciuto del 3%, raggiungendo 561,3 milioni di dollari. L'azienda ha generato un flusso di cassa operativo di 154,4 milioni di dollari e un flusso di cassa libero di 125,4 milioni, mantenendo un leverage netto rettificato di 3,2x.
Inoltre, Avantor ha annunciato un importante cambiamento nella leadership, con la nomina di Emmanuel Ligner come nuovo Presidente e CEO, a partire dal 18 agosto 2025, in sostituzione di Michael Stubblefield.
Avantor (NYSE:AVTR) informó resultados financieros mixtos para el segundo trimestre de 2025, con ventas netas de 1,68 mil millones de dólares, mostrando una disminución del 1% interanual, mientras que los ingresos orgánicos se mantuvieron estables. La compañía reportó un ingreso neto de 64,7 millones de dólares, inferior a los 92,9 millones del segundo trimestre de 2024, con una utilidad diluida por acción de 0,09 dólares y una utilidad ajustada por acción de 0,24 dólares.
El segmento de Laboratory Solutions experimentó una caída del 3% en las ventas netas a 1,12 mil millones de dólares, mientras que Bioscience Production creció un 3%, alcanzando 561,3 millones de dólares. La empresa generó un flujo de caja operativo de 154,4 millones de dólares y un flujo de caja libre de 125,4 millones, manteniendo un apalancamiento neto ajustado de 3,2x.
Además, Avantor anunció un cambio significativo en su liderazgo, con la designación de Emmanuel Ligner como nuevo Presidente y CEO, efectivo a partir del 18 de agosto de 2025, en reemplazo de Michael Stubblefield.
Avantor (NYSE:AVTR)는 2025년 2분기 재무 실적에서 혼재된 결과를 발표했습니다. 순매출은 16억 8천만 달러로 전년 동기 대비 1% 감소했으며, 유기적 매출은 변동이 없었습니다. 회사는 순이익 6,470만 달러를 기록했으며, 이는 2024년 2분기의 9,290만 달러에서 감소한 수치입니다. 희석 주당순이익(EPS)은 0.09달러, 조정 EPS는 0.24달러였습니다.
Laboratory Solutions 부문은 순매출이 3% 감소하여 11억 2천만 달러를 기록한 반면, Bioscience Production 부문은 3% 성장하여 5억 6,130만 달러에 달했습니다. 회사는 영업 현금 흐름 1억 5,440만 달러와 잉여 현금 흐름 1억 2,540만 달러를 창출했으며, 조정 순부채 비율은 3.2배를 유지했습니다.
또한 Avantor는 중대한 리더십 변화를 발표했으며, Emmanuel Ligner가 2025년 8월 18일부터 신임 사장 겸 CEO로 임명되어 Michael Stubblefield를 대신합니다.
Avantor (NYSE:AVTR) a publié des résultats financiers mitigés pour le deuxième trimestre 2025 avec des ventes nettes de 1,68 milliard de dollars, enregistrant une baisse de 1 % par rapport à l'année précédente, tandis que le chiffre d'affaires organique est resté stable. La société a affiché un bénéfice net de 64,7 millions de dollars, en baisse par rapport à 92,9 millions au T2 2024, avec un BPA dilué de 0,09 $ et un BPA ajusté de 0,24 $.
Le segment Laboratory Solutions a connu une baisse de 3 % des ventes nettes à 1,12 milliard de dollars, tandis que Bioscience Production a progressé de 3 % pour atteindre 561,3 millions de dollars. L'entreprise a généré un flux de trésorerie opérationnel de 154,4 millions de dollars et un flux de trésorerie libre de 125,4 millions, maintenant un levier net ajusté de 3,2x.
De plus, Avantor a annoncé un changement important à la tête de l'entreprise, avec la nomination de Emmanuel Ligner en tant que nouveau Président et CEO, à compter du 18 août 2025, en remplacement de Michael Stubblefield.
Avantor (NYSE:AVTR) meldete gemischte Finanzergebnisse für das zweite Quartal 2025 mit Nettoerlösen von 1,68 Milliarden US-Dollar, was einem Rückgang von 1 % im Jahresvergleich entspricht, während der organische Umsatz stabil blieb. Das Unternehmen verzeichnete einen Nettoertrag von 64,7 Millionen US-Dollar, gegenüber 92,9 Millionen US-Dollar im zweiten Quartal 2024, mit einem verwässerten Ergebnis je Aktie (EPS) von 0,09 US-Dollar und einem bereinigten EPS von 0,24 US-Dollar.
Der Geschäftsbereich Laboratory Solutions verzeichnete einen Rückgang der Nettoerlöse um 3 % auf 1,12 Milliarden US-Dollar, während Bioscience Production um 3 % auf 561,3 Millionen US-Dollar wuchs. Das Unternehmen generierte einen operativen Cashflow von 154,4 Millionen US-Dollar und einen freien Cashflow von 125,4 Millionen US-Dollar und hielt eine bereinigte Nettoverschuldung von 3,2x aufrecht.
Darüber hinaus kündigte Avantor eine bedeutende Führungsänderung an, bei der Emmanuel Ligner zum neuen Präsidenten und CEO ernannt wurde, mit Wirkung zum 18. August 2025, als Nachfolger von Michael Stubblefield.
- None.
- Overall net sales decreased 1% year-over-year
- Net income declined 30% to $64.7 million from $92.9 million in Q2 2024
- Laboratory Solutions segment reported 3% sales decline
- Bioscience Production faced challenges from planned maintenance and regulatory issues
Insights
Avantor reports flat organic revenue with margin pressure and leadership transition amid challenges in both business segments.
Avantor's Q2 2025 results reveal a company navigating challenges across its portfolio. The flat organic revenue performance masks divergent trends between segments, with Laboratory Solutions declining 1% organically while Bioscience Production grew 2% organically. The most concerning metrics are on the profitability side, where we see net income dropping 30% year-over-year to
The compressed margins tell an important story. The company's Adjusted EBITDA margin of
Cash generation remains a relative bright spot with free cash flow of
The announced CEO transition from Michael Stubblefield to Emmanuel Ligner on August 18 adds another layer of complexity. Leadership changes during periods of operational challenges can either catalyze improvement or amplify uncertainty. In this case, bringing in a life-sciences veteran suggests the board is seeking fresh perspectives to address the stagnant growth and margin compression.
Contract extensions with leading pharma companies mentioned in the release represent a positive indicator for future stability, though the lack of quantification makes it difficult to assess their material impact. Similarly, while management notes "improvement initiatives" yielding "tangible results" in Laboratory Solutions, the actual organic decline of
- Net sales of
$1.68 billion 1% ; organic revenue was flat - Net income of
$65 million $280 million - Diluted GAAP EPS of
$0.09 $0.24 - Operating cash flow of
$154 million $125 million
"In the second quarter, we remained focused on driving growth, enhancing operating leverage, and executing with discipline," said Michael Stubblefield, President and Chief Executive Officer.
"Our Laboratory Solutions segment delivered sequential revenue growth in line with our expectations, as improvement initiatives began yielding tangible results. We also secured several major contract extensions with leading pharma companies, reinforcing our strong customer relationships and differentiated value proposition. In Bioscience Production, revenue also grew sequentially, though performance was impacted by planned maintenance as well as regulatory and commercial challenges at a few key accounts. We are actively executing mitigation plans and remain encouraged by the continued strength of our core monoclonal antibody platform."
"Avantor's resilient business model, diversified portfolio, and long-standing customer relationships, coupled with our focus on operational excellence, position us to navigate near-term challenges and deliver long-term shareholder value," Stubblefield concluded.
Second Quarter 2025
For the three months ended June 30, 2025, net sales were
Net income decreased to
Diluted earnings per share on a GAAP basis was
Operating cash flow was
Second Quarter 2025 – Segment Results
Laboratory Solutions
- Net sales were
$1,122.1 million 3% , as compared to$1,155.7 million 2% and M&A had a negative impact of4% , resulting in a1% sales decline on an organic basis. - Adjusted Operating Income was
$133.3 million $150.9 million 11.9% .
Bioscience Production
- Net sales were
$561.3 million 3% , as compared to$547.1 million 1% resulting in a2% sales increase on an organic basis. - Adjusted Operating Income was
$139.7 million $144.0 million 24.9% .
Adjusted Operating Income is Avantor's segment reporting profitability measure under generally accepted accounting principles and is used by management to measure and evaluate the performance of our Company's business segments.
CEO Transition
As previously announced on July 21, Avantor has named life-sciences veteran Emmanuel Ligner as its next President and Chief Executive Officer, effective August 18, 2025. Mr. Ligner succeeds Michael Stubblefield, who will step down from his role as Director, President and Chief Executive Officer upon Mr. Ligner's appointment.
Conference Call
We will host a conference call to discuss our results today, August 1, 2025, at 8:00 a.m. Eastern Time. The live webcast, presentation and supplemental disclosure package, as well as a replay, will be available on the investor section of Avantor's website.
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
Use of Non-GAAP Financial Measures
To evaluate our performance, we monitor a number of key indicators. As appropriate, we supplement our results of operations determined in accordance with
The non-GAAP financial measures used in this press release are sales growth (decline) on an organic basis, Adjusted Operating Income, Adjusted Operating Income margin, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income, adjusted EPS, adjusted net leverage, free cash flow and free cash flow conversion.
- Organic net sales growth (decline) eliminates from our reported net sales change the impacts of revenues from acquisitions and divestitures that occurred in the last year (as applicable) and changes in foreign currency exchange rates. We believe that this measurement is useful to investors as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented. This measure is used by our management for the same reason.
- Adjusted Operating Income is our net income or loss adjusted for the following items: (i) interest expense, (ii) income tax expense, (iii) amortization of acquired intangible assets, (iv) losses on extinguishment of debt, (v) charges associated with the impairment of certain assets, (vi) gain on sale of business, and (vii) certain other adjustments. Adjusted Operating Income margin is Adjusted Operating Income divided by net sales as determined under GAAP. We believe that these measures are useful to investors as ways to analyze the underlying trends in our business consistently across the periods presented. These measures are used by our management for the same reason. Additionally, Adjusted Operating Income is our segment reporting profitability measure under GAAP.
- Adjusted EBITDA is our net income or loss adjusted for the following items: (i) interest expense, (ii) income tax expense, (iii) amortization of acquired intangible assets, (iv) depreciation expense, (v) losses on extinguishment of debt, (vi) charges associated with the impairment of certain assets, (vii) gain on sale of business, and (viii) certain other adjustments. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP. We believe that these measures are useful to investors as ways to analyze the underlying trends in our business consistently across the periods presented. These measures are used by our management for the same reason.
- Adjusted net income is our net income or loss first adjusted for the following items: (i) amortization of acquired intangible assets, (ii) losses on extinguishment of debt, (iii) charges associated with the impairment of certain assets, (iv) gain on sale of business, and (v) certain other adjustments. From this amount, we then add or subtract an assumed incremental income tax impact on the above-noted pre-tax adjustments, using estimated tax rates, to arrive at Adjusted Net Income. We believe that this measure is useful to investors as a way to analyze the business consistently across the periods presented. This measure is used by our management for the same reason.
- Adjusted EPS is our adjusted net income divided by our diluted GAAP weighted average share count adjusted for anti-dilutive instruments. We believe that this measure is useful to investors as an additional way to analyze the underlying trends in our business consistently across the periods presented. This measure is used by our management for the same reason.
- Adjusted net leverage is equal to our gross debt, reduced by our cash and cash equivalents, divided by our trailing 12-month Adjusted EBITDA (excluding stock-based compensation expense and including the expected run-rate effect of cost synergies and the incremental results of completed acquisitions and divestitures as if those acquisitions and divestitures had occurred on the first day of the trailing 12-month period). We believe that this measure is useful to investors as a way to evaluate and measure the Company's capital allocation strategies and the underlying trends in the business. This measure is used by our management for the same reason.
- Free cash flow is equal to our cash flows from operating activities, less capital expenditures, plus direct transaction costs and income taxes paid related to acquisitions and divestitures (as applicable) in the period. Free cash flow conversion is free cash flow divided by adjusted net income. We believe that these measures are useful to investors as they provide a view on the Company's ability to generate cash for use in financing or investing activities. These measures are used by our management for the same reason.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.
Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, including our cost transformation initiative, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "assumption," "believe," "continue," "estimate," "expect," "forecast," "goal," "guidance," "intend," "likely," "long-term," "near-term," "objective," "opportunity," "outlook," "plan," "potential," "project," "projection," "prospects," "seek," "target," "trend," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.
Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.
Investor Relations Contact
Allison Hosak
Senior Vice President, Global Communications
Avantor
908-329-7281
Allison.Hosak@avantorsciences.com
Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.Vanzanten@avantorsciences.com
Avantor, Inc. and subsidiaries | |||||||
(in millions, except per share data) | Three months ended | Six months ended | |||||
2025 | 2024 | 2025 | 2024 | ||||
Net sales | $ 1,683.4 | $ 1,702.8 | $ 3,264.8 | $ 3,382.6 | |||
Cost of sales | 1,129.3 | 1,121.3 | 2,175.8 | 2,230.6 | |||
Gross profit | 554.1 | 581.5 | 1,089.0 | 1,152.0 | |||
Selling, general and administrative expenses | 425.3 | 405.7 | 812.8 | 829.9 | |||
Operating income | 128.8 | 175.8 | 276.2 | 322.1 | |||
Interest expense, net | (43.4) | (60.9) | (85.6) | (125.2) | |||
Loss on extinguishment of debt | — | (1.9) | — | (4.4) | |||
Other (expense) income, net | (3.7) | 1.6 | (23.2) | 2.7 | |||
Income before income taxes | 81.7 | 114.6 | 167.4 | 195.2 | |||
Income tax expense | (17.0) | (21.7) | (38.2) | (41.9) | |||
Net income | $ 64.7 | $ 92.9 | $ 129.2 | $ 153.3 | |||
Earnings per share: | |||||||
Basic | $ 0.09 | $ 0.14 | $ 0.19 | $ 0.23 | |||
Diluted | $ 0.09 | $ 0.14 | $ 0.19 | $ 0.22 | |||
Weighted average shares outstanding: | |||||||
Basic | 681.5 | 679.4 | 681.3 | 678.7 | |||
Diluted | 681.8 | 682.6 | 682.0 | 681.9 | |||
Avantor, Inc. and subsidiaries | |||
(in millions) | June 30, 2025 | December 31, 2024 | |
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ 449.4 | $ 261.9 | |
Accounts receivable, net | 1,149.4 | 1,034.5 | |
Inventory | 779.8 | 731.5 | |
Other current assets | 136.0 | 118.7 | |
Total current assets | 2,514.6 | 2,146.6 | |
Property, plant and equipment, net | 759.0 | 708.1 | |
Other intangible assets, net | 3,350.2 | 3,360.2 | |
Goodwill, net | 5,762.2 | 5,539.2 | |
Other assets | 390.9 | 360.4 | |
Total assets | $ 12,776.9 | $ 12,114.5 | |
Liabilities and stockholders' equity | |||
Current liabilities: | |||
Current portion of debt | $ 1,254.3 | $ 821.1 | |
Accounts payable | 708.8 | 662.8 | |
Employee-related liabilities | 174.0 | 168.2 | |
Accrued interest | 50.0 | 48.6 | |
Other current liabilities | 388.6 | 306.8 | |
Total current liabilities | 2,575.7 | 2,007.5 | |
Debt, net of current portion | 2,988.2 | 3,234.7 | |
Deferred income tax liabilities | 535.7 | 557.3 | |
Other liabilities | 391.4 | 358.3 | |
Total liabilities | 6,491.0 | 6,157.8 | |
Stockholders' equity: | |||
Common stock including paid-in capital | 3,964.1 | 3,937.7 | |
Accumulated earnings | 2,332.2 | 2,203.0 | |
Accumulated other comprehensive loss | (10.4) | (184.0) | |
Total stockholders' equity | 6,285.9 | 5,956.7 | |
Total liabilities and stockholders' equity | $ 12,776.9 | $ 12,114.5 | |
Avantor, Inc. and subsidiaries | |||||||
(in millions) | Three months ended | Six months ended | |||||
2025 | 2024 | 2025 | 2024 | ||||
Cash flows from operating activities: | |||||||
Net income | $ 64.7 | $ 92.9 | $ 129.2 | $ 153.3 | |||
Reconciling adjustments: | |||||||
Depreciation and amortization | 102.7 | 102.6 | 202.4 | 202.2 | |||
Stock-based compensation expense | 15.5 | 11.1 | 27.9 | 23.8 | |||
Provision for accounts receivable and | 14.9 | 15.5 | 26.9 | 39.5 | |||
Deferred income tax benefit | (17.6) | (34.8) | (30.0) | (52.7) | |||
Amortization of deferred financing costs | 2.3 | 2.8 | 4.5 | 5.8 | |||
Loss on extinguishment of debt | — | 1.9 | — | 4.4 | |||
Foreign currency remeasurement loss (gain) | 1.9 | (2.2) | 3.8 | 3.1 | |||
Pension termination charges | — | — | 18.1 | — | |||
Changes in assets and liabilities: | |||||||
Accounts receivable | (12.5) | (2.7) | (55.7) | — | |||
Inventory | (15.7) | (3.2) | (33.3) | (14.2) | |||
Accounts payable | 10.9 | 89.5 | 19.1 | 45.9 | |||
Accrued interest | 10.7 | 9.2 | 1.4 | (0.3) | |||
Other assets and liabilities | (23.8) | (2.9) | (52.9) | 6.4 | |||
Other | 0.4 | 1.4 | 2.3 | 5.5 | |||
Net cash provided by operating activities | 154.4 | 281.1 | 263.7 | 422.7 | |||
Cash flows from investing activities: | |||||||
Capital expenditures | (29.6) | (45.8) | (57.6) | (80.5) | |||
Other | 1.0 | 0.9 | 0.1 | 1.4 | |||
Net cash used in investing activities | (28.6) | (44.9) | (57.5) | (79.1) | |||
Cash flows from financing activities: | |||||||
Debt borrowings | — | (28.9) | — | 12.3 | |||
Debt repayments | (6.8) | (172.7) | (38.1) | (383.0) | |||
Proceeds received from exercise of stock options | — | 5.3 | 2.6 | 50.8 | |||
Shares repurchased to satisfy employee tax | (0.1) | (0.8) | (5.0) | (7.4) | |||
Net cash used in financing activities | (6.9) | (197.1) | (40.5) | (327.3) | |||
Effect of currency rate changes on cash and cash | 14.8 | (1.6) | 21.8 | (7.3) | |||
Net change in cash, cash equivalents and restricted | 133.7 | 37.5 | 187.5 | 9.0 | |||
Cash, cash equivalents and restricted cash, beginning | 318.5 | 259.2 | 264.7 | 287.7 | |||
Cash, cash equivalents and restricted cash, end of | $ 452.2 | $ 296.7 | $ 452.2 | $ 296.7 | |||
Avantor, Inc. and subsidiaries | |||||||||||||||
(dollars in millions, % | Three months ended June 30, | Six months ended June 30, | |||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||
$ | % | $ | % | $ | % | $ | % | ||||||||
Net income | $ 64.7 | 3.8 % | $ 92.9 | 5.5 % | 4.0 % | 4.5 % | |||||||||
Amortization | 75.5 | 4.5 % | 74.9 | 4.4 % | 149.4 | 4.6 % | 150.2 | 4.4 % | |||||||
Loss on extinguishment | — | — % | 1.9 | — % | — | — % | 4.4 | 0.1 % | |||||||
Restructuring and | 21.4 | 1.3 % | 9.7 | 0.6 % | 25.8 | 0.8 % | 32.9 | 1.0 % | |||||||
Transformation | 20.4 | 1.2 % | 16.2 | 1.0 % | 35.8 | 1.1 % | 29.5 | 0.9 % | |||||||
Reserve for certain legal | 3.6 | 0.2 % | — | — % | 3.6 | 0.1 % | — | — % | |||||||
Other4 | 6.6 | 0.4 % | (0.3) | — % | 10.6 | 0.3 % | (0.8) | — % | |||||||
Pension termination | — | — % | — | — % | 18.1 | 0.6 % | — | — % | |||||||
Income tax benefit | (31.0) | (1.8) % | (27.3) | (1.6) % | (56.1) | (1.8) % | (50.9) | (1.5) % | |||||||
Adjusted net income | 161.2 | 9.6 % | 168.0 | 9.9 % | 316.4 | 9.7 % | 318.6 | 9.4 % | |||||||
Interest expense, net | 43.4 | 2.6 % | 60.9 | 3.6 % | 85.6 | 2.6 % | 125.2 | 3.7 % | |||||||
Depreciation | 27.2 | 1.6 % | 27.7 | 1.5 % | 53.0 | 1.6 % | 52.0 | 1.6 % | |||||||
Income tax provision | 48.0 | 2.8 % | 49.0 | 2.9 % | 94.3 | 2.9 % | 92.8 | 2.7 % | |||||||
Adjusted EBITDA | 16.6 % | 17.9 % | 16.8 % | 17.4 % | |||||||||||
━━━━━━━━━ | |
1. | Reflects the incremental expenses incurred in the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption are specific to employee severance, site-related exit costs, and contract termination costs. These expenses represent costs incurred to achieve the Company's publicly-announced cost transformation initiative. |
2. | Represents incremental expenses directly associated with the Company's publicly-announced cost transformation initiative, primarily related to the cost of external advisors. |
3. | Represents charges and legal costs, net of recoveries, in connection with certain litigation and other contingencies that are unrelated to our core operations and not reflective of on-going business and operating results. |
4. | Represents net foreign currency (gain) loss from financing activities, other stock-based compensation expense (benefit) and a purchase price adjustment related to the sale of our Clinical Services business in 2024. |
5. | Represents pension termination charges related to termination of our |
Avantor, Inc. and subsidiaries | |||||||||||||||
(dollars in millions, % based on | Three months ended June 30, | Six months ended June 30, | |||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||
$ | % | $ | % | $ | % | $ | % | ||||||||
Net income | $ 64.7 | 3.8 % | $ 92.9 | 5.5 % | $ 129.2 | 4.0 % | $ 153.3 | 4.5 % | |||||||
Interest expense, net | 43.4 | 2.6 % | 60.9 | 3.6 % | 85.6 | 2.6 % | 125.2 | 3.7 % | |||||||
Income tax expense | 17.0 | 1.0 % | 21.7 | 1.3 % | 38.2 | 1.1 % | 41.9 | 1.2 % | |||||||
Loss on extinguishment | — | — % | 1.9 | — % | — | — % | 4.4 | 0.1 % | |||||||
Other (expense) income, net | 3.7 | 0.3 % | (1.6) | (0.1) % | 23.2 | 0.8 % | (2.7) | — % | |||||||
Operating income | 128.8 | 7.7 % | 175.8 | 10.3 % | 276.2 | 8.5 % | 322.1 | 9.5 % | |||||||
Amortization | 75.5 | 4.5 % | 74.9 | 4.4 % | 149.4 | 4.6 % | 150.2 | 4.4 % | |||||||
Restructuring and severance | 21.4 | 1.3 % | 9.7 | 0.6 % | 25.8 | 0.8 % | 32.9 | 1.0 % | |||||||
Transformation expenses2 | 20.4 | 1.2 % | 16.2 | 1.0 % | 35.8 | 1.1 % | 29.5 | 0.9 % | |||||||
Reserve for certain legal | 3.6 | 0.2 % | — | — % | 3.6 | 0.1 % | — | — % | |||||||
Other4 | 2.5 | 0.1 % | 0.6 | — % | 4.2 | 0.1 % | 0.9 | — % | |||||||
Adjusted Operating Income | $ 252.2 | 15.0 % | $ 277.2 | 16.3 % | $ 495.0 | 15.2 % | $ 535.6 | 15.8 % | |||||||
━━━━━━━━━ | |
1. | Reflects the incremental expenses incurred in the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption are specific to employee severance, site-related exit costs, and contract termination costs. These expenses represent costs incurred to achieve the Company's publicly-announced cost transformation initiative. |
2. | Represents incremental expenses directly associated with the Company's publicly-announced cost transformation initiative, primarily related to the cost of external advisors. |
3. | Represents charges and legal costs, net of recoveries, in connection with certain litigation and other contingencies that are unrelated to our core operations and not reflective of on-going business and operating results. |
4. | Represents other stock-based compensation expense (benefit) and a purchase price adjustment related to the sale of our Clinical Services business in 2024. |
Avantor, Inc. and subsidiaries | |||||||
(shares in millions) | Three months ended | Six months ended | |||||
2025 | 2024 | 2025 | 2024 | ||||
Diluted earnings per share (GAAP) | $ 0.09 | $ 0.14 | $ 0.19 | $ 0.22 | |||
Dilutive impact of convertible instruments | — | — | — | — | |||
Fully diluted earnings per share (non-GAAP) | 0.09 | 0.14 | 0.19 | 0.22 | |||
Amortization | 0.11 | 0.11 | 0.22 | 0.22 | |||
Loss on extinguishment of debt | — | — | — | 0.01 | |||
Restructuring and severance charges | 0.03 | 0.02 | 0.04 | 0.05 | |||
Transformation expenses | 0.03 | 0.02 | 0.04 | 0.04 | |||
Reserve for certain legal matters, net | 0.01 | — | 0.01 | — | |||
Other | 0.02 | — | 0.01 | — | |||
Pension termination charges | — | — | 0.03 | — | |||
Income tax benefit applicable to pretax adjustments | (0.05) | (0.04) | (0.08) | (0.07) | |||
Adjusted EPS (non-GAAP) | $ 0.24 | $ 0.25 | $ 0.46 | $ 0.47 | |||
Weighted average diluted shares outstanding: | |||||||
Share count for Adjusted EPS (non-GAAP) | 681.8 | 682.6 | 682.0 | 681.9 | |||
Free cash flow | |||||||
(in millions) | Three months ended | Six months ended | |||||
2025 | 2024 | 2025 | 2024 | ||||
Net cash provided by operating activities | $ 154.4 | $ 281.1 | $ 263.7 | $ 422.7 | |||
Capital expenditures | (29.6) | (45.8) | (57.6) | (80.5) | |||
Divestiture-related transaction expenses and taxes | 0.6 | — | 1.4 | — | |||
Free cash flow (non-GAAP) | $ 125.4 | $ 235.3 | $ 207.5 | $ 342.2 | |||
Adjusted net leverage | |
(dollars in millions) | June 30, 2025 |
Total debt, gross | $ 4,261.0 |
Less cash and cash equivalents | (449.4) |
$ 3,811.6 | |
Trailing twelve months Adjusted EBITDA(1) | $ 1,141.8 |
Trailing twelve months ongoing stock-based compensation expense | 51.8 |
$ 1,193.6 | |
Adjusted net leverage (non-GAAP) | 3.2 x |
1. | Represents the Adjusted EBITDA of Avantor for the trailing twelve-month period minus the results attributable to the divested business as if such divestiture had been completed on the first day of such trailing twelve-month period, as contemplated by our debt covenants. |
Avantor, Inc. and subsidiaries | |||||||||||
(in millions) | June 30, | Reconciliation of net sales growth (decline) to | |||||||||
Net sales | Foreign | Divestiture | Organic | ||||||||
2025 | 2024 | ||||||||||
$ | $ | $ | $ | $ | $ | ||||||
Three months ended: | |||||||||||
Laboratory Solutions | $ 1,122.1 | $ 1,155.7 | $ (33.6) | $ 25.6 | $ (48.1) | $ (11.1) | |||||
Bioscience Production | 561.3 | 547.1 | 14.2 | 5.8 | — | 8.4 | |||||
Total | $ 1,683.4 | $ 1,702.8 | $ (19.4) | $ 31.4 | $ (48.1) | $ (2.7) | |||||
Six months ended: | |||||||||||
Laboratory Solutions | $ 2,187.1 | $ 2,312.8 | $ (125.7) | $ 11.1 | $ (92.2) | $ (44.6) | |||||
Bioscience Production | 1,077.7 | 1,069.8 | 7.9 | 1.3 | — | 6.6 | |||||
Total | $ 3,264.8 | $ 3,382.6 | $ (117.8) | $ 12.4 | $ (92.2) | $ (38.0) | |||||
(dollars in millions, % based | June 30, | Reconciliation of net sales growth (decline) to | |||||||||
Net sales | Foreign | Divestiture | Organic | ||||||||
2025 | 2024 | ||||||||||
$ | $ | % | % | % | % | ||||||
Three months ended: | |||||||||||
Laboratory Solutions | $ 1,122.1 | $ 1,155.7 | (2.9) % | 2.3 % | (4.2) % | (1.0) % | |||||
Bioscience Production | 561.3 | 547.1 | 2.6 % | 1.1 % | — % | 1.5 % | |||||
Total | $ 1,683.4 | $ 1,702.8 | (1.1) % | 1.9 % | (2.8) % | (0.2) % | |||||
Six months ended: | |||||||||||
Laboratory Solutions | $ 2,187.1 | $ 2,312.8 | (5.4) % | 0.5 % | (4.0) % | (1.9) % | |||||
Bioscience Production | 1,077.7 | 1,069.8 | 0.7 % | 0.1 % | — % | 0.6 % | |||||
Total | $ 3,264.8 | $ 3,382.6 | (3.5) % | 0.3 % | (2.7) % | (1.1) % | |||||
Adjusted Operating Income by segment | |||||||||||||||
(dollars in millions, % | Three months ended June 30, | Six months ended June 30, | |||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||
$ | % | $ | % | $ | % | $ | % | ||||||||
Laboratory Solutions | 11.9 % | 13.1 % | 12.5 % | 12.9 % | |||||||||||
Bioscience Production | 139.7 | 24.9 % | 144.0 | 26.3 % | 263.1 | 24.4 % | 270.9 | 25.3 % | |||||||
Corporate | (20.8) | — % | (17.7) | — % | (40.4) | — % | (34.4) | — % | |||||||
Total | 15.0 % | 16.3 % | 15.2 % | 15.8 % | |||||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-reports-second-quarter-2025-results-302519338.html
SOURCE Avantor and Financial News
FAQ
What were Avantor's (AVTR) key financial results for Q2 2025?
Who is the new CEO of Avantor (AVTR) and when does the transition occur?
How did Avantor's Laboratory Solutions segment perform in Q2 2025?
What was Avantor's (AVTR) Bioscience Production segment performance in Q2 2025?
What is Avantor's current adjusted net leverage ratio?
